Brokerages Set TuHURA Biosciences, Inc. (NASDAQ:HURA) Target Price at $12.67

Shares of TuHURA Biosciences, Inc. (NASDAQ:HURA) have been assigned an average recommendation of “Buy” from the five ratings firms that are presently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $12.6667.

Several research firms recently commented on HURA. Brookline Capital Management raised shares of TuHURA Biosciences to a “strong-buy” rating in a research report on Monday, June 23rd. Wall Street Zen raised shares of TuHURA Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, July 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of TuHURA Biosciences in a research report on Friday, May 16th.

Institutional Investors Weigh In On TuHURA Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in HURA. JPMorgan Chase & Co. bought a new stake in TuHURA Biosciences during the 2nd quarter worth about $27,000. Intech Investment Management LLC bought a new stake in TuHURA Biosciences during the 2nd quarter worth about $29,000. Invesco Ltd. bought a new stake in TuHURA Biosciences during the 2nd quarter worth about $30,000. Merck & Co. Inc. bought a new stake in TuHURA Biosciences during the 2nd quarter worth about $31,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in TuHURA Biosciences during the 2nd quarter worth about $31,000. 0.62% of the stock is owned by institutional investors.

TuHURA Biosciences Price Performance

Shares of HURA stock opened at $3.06 on Wednesday. TuHURA Biosciences has a 12-month low of $1.80 and a 12-month high of $8.63. The firm has a fifty day moving average of $2.58 and a 200-day moving average of $3.21.

TuHURA Biosciences (NASDAQ:HURA) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02).

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.